Literature DB >> 9199878

Effects of prolactin and metoclopramide on macrophage cytokine gene expression in late sepsis.

X H Zhu1, R Zellweger, M W Wichmann, A Ayala, I H Chaudry.   

Abstract

Previous studies indicate a profound suppression of tumour necrosis factor alpha (TNF-gamma), IL-1 beta and IL-6 release capacity by peritoneal macrophage (PM phi), splenic macrophage (SM phi) and Kupffer cells (KC) during late sepsis. Such a loss of functional capacity may reduce the animal's ability to ward off infection. Prolactin is known to enhance monocyte, T- and B-lymphocyte immune responses under normal conditions and has beneficial effects on cell-mediated immunity after haemorrhage. In the respect, the dopamine antagonist, metoclopramide, has been reported to increase circulating prolactin levels. Nonetheless, it remains unknown whether prolactin or metoclopramide have any salutary effect on macrophage (M phi) cytokine gene expression following sepsis. To study this, male C3H/HeN mice were subjected to sepsis and immediately thereafter were treated with prolactin (100 micrograms/25 g body weight, s.c.), metoclopramide (100 micrograms/100 g BW, s.c.) or given saline. PM phi, SM phi and KC (only SM phi and KC in metoclopramide-treated animals) were isolated at 24 h after sepsis. The monolayers were stimulated with or without LPS 10 micrograms/ml for 1 h in vitro. Total RNA was extracted and mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). A significant depression of constitutive and inducible mRNA levels of IL-1 beta, IL-6 and TNF-alpha in all three M phi populations were observed, when compared with shams (with exception of KC IL-6 mRNA in unstimulated cells). Prolactin as well as metoclopramide treatment after the onset of sepsis caused significant elevation of constitutive and inducible cytokine gene expression in all macrophages examined. Thus, prolactin and metoclopramide enhance the depressed M phi gene expression and may be useful in improving cell-mediated immunity during sepsis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199878     DOI: 10.1006/cyto.1996.0186

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

Review 1.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  [Effects of dopamine on cellular and humoral immune responses in septic patients].

Authors:  G Beck; C Hanusch; P Brinkkoetter; N Rafat; J Schulte; K van Ackern; B Yard
Journal:  Anaesthesist       Date:  2005-10       Impact factor: 1.041

Review 3.  Dopaminergic Regulation of Innate Immunity: a Review.

Authors:  Monica Pinoli; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2017-06-03       Impact factor: 4.147

Review 4.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

5.  Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure.

Authors:  Yanrong Zhang; Santiago Cuevas; Laureano D Asico; Crisanto Escano; Yu Yang; Annabelle M Pascua; Xiaoyan Wang; John E Jones; David Grandy; Gilbert Eisner; Pedro A Jose; Ines Armando
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

Review 6.  Clinical review: immunomodulatory effects of dopamine in general inflammation.

Authors:  Grietje Ch Beck; Paul Brinkkoetter; Christine Hanusch; Jutta Schulte; Klaus van Ackern; Fokko J van der Woude; Benito A Yard
Journal:  Crit Care       Date:  2004-06-03       Impact factor: 9.097

7.  Cerebrospinal fluid dynamics modulation by diet and cytokines in rats.

Authors:  Zerin Alimajstorovic; Ester Pascual-Baixauli; Cheryl A Hawkes; Basil Sharrack; A Jane Loughlin; Ignacio A Romero; Jane E Preston
Journal:  Fluids Barriers CNS       Date:  2020-02-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.